3/11
08:32 am
cero
CERo Therapeutics Provides Shareholder Update [Yahoo! Finance]
Low
Report
CERo Therapeutics Provides Shareholder Update [Yahoo! Finance]
3/11
08:15 am
cero
CERo Therapeutics Provides Shareholder Update
Low
Report
CERo Therapeutics Provides Shareholder Update
2/17
08:00 am
cero
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
High
Report
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
2/4
09:27 am
cero
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient [Yahoo! Finance]
Medium
Report
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient [Yahoo! Finance]
2/4
09:05 am
cero
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
Medium
Report
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
1/7
09:09 am
cero
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
Medium
Report
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML